Watchlist Price Alert

CureVac N.V. (CVAC)

NASDAQ: CVAC · Real-Time Price · USD

5.54

-0.03 (-0.54%)

At close: Jun 16, 2025, 3:59 PM

5.44

-1.72%

Pre-market: Jun 17, 2025, 04:02 AM EDT

-0.54% (1D)

Bid	5.43
Market Cap	1.25B
Revenue (ttm)	535.18M
Net Income (ttm)	162.19M
EPS (ttm)	0.92
PE Ratio (ttm)	6.02
Forward PE	-11.16
Analyst	Buy

Ask	5.52
Volume	1,397,417
Avg. Volume (20D)	1,082,995
Open	5.53
Previous Close	5.57
Day's Range	5.48 - 5.56
52-Week Range	2.37 - 5.72
Beta	2.49

About CVAC

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CVAC

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CVAC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

5 days ago

+37.59%

CureVac shares are trading higher after BioNTech a... Unlock content with Pro Subscription

4 weeks ago

+10.59%

CureVac shares are trading higher following Q1 reported financial results.

News

4 days ago · investopedia.com

Top Stock Movers Now: Oracle, Boeing, CureVac, and More

U.S. equities were mixed and little changed at midday as another key measure of inflation, the Producer Price Index (PPI), came in lower than expected. The S&P 500 and Nasdaq advanced, while the Dow J...

5 days ago · schaeffersresearch.com

CureVac Stock Soars on BioNTech Buyout

Biotech stock CureVac NV (NASDAQ:CVAC) was last seen up 32.2% at $5.37, after news that BioNTech (BNTX) is acquiring the company in all-stock deal worth $1.25 billion.

5 days ago · benzinga.com

BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal

BioNTech SE BNTX on Thursday agreed to acquire CureVac N.V. CVAC in an all-stock transaction.

5 days ago · proactiveinvestors.com

BioNTech boosts cancer mRNA pipeline with CureVac acquisition

BioNTech (NASDAQ:BNTX) announced that it is acquiring CureVac (NASDAQ:CVAC), a fellow German mRNA vaccine developer, in an all-stock deal valued at approximately $1.25 billion. Under the deal terms, e...

5 days ago · businesswire.com

CVAC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CureVac N.V. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of CureVac N.V. (NASDAQ: CVAC) to BioNTech SE is fair to CureVac shareholders. Under the ter...

5 days ago · barrons.com

BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.

CureVac stock soared 29% $5.26 in premarket trading immediately following the news.

5 days ago · reuters.com

BioNTech to acquire CureVac in $1.25 billion all-stock deal

German biotech firm BioNTech said on Thursday it agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares to boost its work on new mRNA-based cancer treatments.

4 weeks ago · accessnewswire.com

CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates

U.S. FDA clears lung cancer IND for CVHNLC, a proprietary off-the-shelf candidate targeting squamous non-small cell lung cancer (sqNCLC), with clinical study expected to begin H2 2025; Clinical Trial ...

1 month ago · accessnewswire.com

CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE

European Patent Office largely dismisses opposition filed by BioNTech SE, Pfizer Inc., and others in December 2023 challenging validity of EP 4 023 755 B1 and maintains the patent subject to amendment...

2 months ago · seekingalpha.com

CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript

CureVac N.V. (NASDAQ:CVAC ) Q4 2024 Earnings Conference Call April 10, 2025 9:00 AM ET Company Participants Sarah Fakih - Vice President, Corporate Communications and Investor Relations Alexander Zehn...

Load More News